The EPS projection of EnteroMedics Inc. (NASDAQ:ETRM) for quarter ended 2016-09-30 is $-0.67. Last week, the projection for EPS was $-0.67 against target of $-0.67, a month earlier. While 2-months ago, this projection was $-0.67 versus forecast of $-0.67a quarter months earlier, posting a deviation of 0%.
EnteroMedics Inc. (NASDAQ:ETRM) posted that 18 days earlier, the share price was revised 1 times on upside. In addition, negative revisions were 0.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 0, and 0, correspondingly.
The per-share earnings downgrade for EnteroMedics Inc. (NASDAQ:ETRM) in the preceding 30 and 120 were 0 and 1. While in 60 and 90 days were 1, and 1, in that order.
EnteroMedics Inc. (NASDAQ:ETRM) EPS target was $-0.67 for the quarter closed 1. It was based on 2 calls. As on 2016-05-05 the EPS was $-0.82. The change was $-0.02, posting a deviation of -2.5%. The price projections gave a standard deviation of 0.
Quarterly Sales Estimates
EnteroMedics Inc. (NASDAQ:ETRM) sales prediction for the fiscal 2016 stands at $0.295 and the median estimate is at $0.295. Almost 2 analysts gave sales target.
Among this, the highest sales estimate is $0.39 while the lowest target is $0.2 showing standard deviation of 0.134%.
As many as 2 analysts have positive sales targets revision while 2 reduced sales estimates, posting a deviation of 0%.
Last month, 2 experts have positive sales number revision. Also, 2 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast, posting a deviation of -47.787%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...